within Pharmacolibrary.Drugs.ATC.J;

model J05AX28
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.243 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.00332,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bulevirtide is an entry inhibitor used for the treatment of chronic hepatitis B and D virus infection. It acts by binding to and blocking the sodium taurocholate co-transporting polypeptide (NTCP) receptor on hepatocytes, thereby preventing viral entry. Bulevirtide is approved for medical use in the European Union for chronic hepatitis D infection in adults with compensated liver disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following subcutaneous administration; population pharmacokinetic modeling.</p><h4>References</h4><ol><li><p>Zhu, V, et al., &amp; Blank, A (2023). Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers. <i>Frontiers in pharmacology</i> 14 1128547â€“None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2023.1128547&quot;>10.3389/fphar.2023.1128547</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37089922/&quot;>https://pubmed.ncbi.nlm.nih.gov/37089922</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AX28;
